SCHEMBL87545

SCHEMBL87545

O=C(NCC1CCc2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C1)OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44
CYP2C9 P11712 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39
KCNE1 P15382 1/20 0.38
CCR1 P32246 1/20 0.38
KCNQ1 P51787 1/20 0.38
TP53 P04637 3/20 0.38
PLAU P00749 1/20 0.38
CNR2 P34972 1/20 0.38
ERCC1 P07992 1/20 0.38
FEN1 P39748 1/20 0.38
ERCC4 Q92889 1/20 0.38
ALDH1A1 P00352 1/20 0.37
TNKS O95271 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13691809 0.94 KCNH2 (0.45) KCNH2CYP2C9SMN1; SMN2MAPTL3MBTL1
SCHEMBL87288 0.83 KCNH2 (0.44) KCNH2CYP2C9SMN1; SMN2MAPTL3MBTL1
SCHEMBL13691728 0.81 KCNH2 (0.53) KCNH2CYP2C9SMN1; SMN2MAPTLMNA
SCHEMBL13691707 0.80 KCNH2 (0.46) KCNH2CYP2C9SMN1; SMN2MAPTLMNA
SCHEMBL1380510 0.79 KCNH2 (0.51) KCNH2CYP2C9SMN1; SMN2MAPTLMNA
SCHEMBL5097935 0.79 KCNH2 (0.51) KCNH2CYP2C9SMN1; SMN2MAPTLMNA
SCHEMBL13691632 0.79 CYP2C9 (0.43) KCNH2CYP2C9SMN1; SMN2MAPTL3MBTL1
SCHEMBL62281 0.77 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2MAPTL3MBTL1
SCHEMBL87844 0.77 KCNH2 (0.52) KCNH2CYP2C9SMN1; SMN2MAPTLMNA
SCHEMBL87440 0.77 KCNH2 (0.49) KCNH2CYP2C9SMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885SMN1; SMN2 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.